|
The information is updated the first week of every month - so ... make this a regular stop in your information gathering activities.The following information has been compiled from publicly available sources, StratCom does not assume any responsibility for the accuracy or the authenticity of the information and StratCom cannot be held liable for errors.
Dear Readers, The summer flew by and as promised here are this summer's news highlights. Our monthly revisions begin in September. Happy Reading and Best Regards, Shara Rosen Agilent Technologies Inc. has introduced the Agilent Human 1B Oligo Microarray Kit for gene expression analysis in drug discovery and disease research. Together with the existing Agilent Human 1A Oligo Microarray Kit, the two-microarray set includes more than 36,000 genes and transcripts. Agendia B.V. is developing a microarray-based diagnostic test to predict the aggressiveness of breast cancer tumors using Agilent's array platform.. Ambion RNA Diagnostics, a division of Ambion, Inc. has introduced a control for detection of the coronavirus associated with Severe Acute Respiratory Syndrome (SARS). The Armored RNA portfolio of products is available for purchase through Boston Biomedica, Inc. Ambion has been granted an exclusive worldwide research market license from City of Hope National Medical Center and Beckman Research Institute for technology detailed in a patent application covering technologies for expressing small interfering RNA (siRNA) from PCR products. Centrex, Inc. and Micronics, Inc. are working together to design and develop disposable, multipurpose microfluidics lab cards that incorporate Centrex's single molecule nucleic acid detection ("SMD") technology. Esoterix has launched its MODYdetXSM (MODY-3) assay for the identification of diabetes patients with MODY-3, short for Maturity Onset Diabetes of Youth type 3. MODYdetX is used to provide a definitive diagnosis for patients with a form of non-insulin dependent diabetes. MetriGenix Inc. has introduced the MGX 4D Respiratory Virus Panel Array for research and study of markers related to major viral respiratory agents including influenza viruses, para influenza viruses, pneumoviruses (RSV-A and RSV-B viruses), metapneumovirus, corona viruses (229E, OC43 and SARS), mumps virus and measles virus. The chip will be commercially available in the latter half of 2003. Mount Sinai School of Medicine and Hamilton Thorne Biosciences, Inc. has been issued a US patent, "Nucleic Acid Amplification Method: Ramification Extension Amplification Method (RAM). Using the newly patented technology, Hamilton Thorne Biosciences will develop a family of diagnostic instruments and reagents for applications in medicine, research, drug development, food safety, and environmental testing. Roche Diagnostics has launched its AmpliChip CYP450 microarray in the US. The chip tests for polymorphisms in two genes, the CYP2D6 and CYP2C19, which play a major role in drug metabolism. Roche developed the AmpliChip CYP450 microarray on the Affymetrix microarray platform. Roche had anticipated to sell the AmpliChip CYP450 microarray initially as an Analyte Specific Reagent, however the FDA has invited Roche to discuss the proper classification of the device. Roche expects the test to be available as an in vitro diagnostic in the United States and Europe later in 2004.
Product Developments Worldwide | Research News | Health Care in Canada Information Technology and Healthcare | Molecular Biology | Links
![[HRule Image]](images/div.jpg){kind=small} Send mail to stratcom@pagebleu.com with questions or comments about this web site.Concept and Design Blue Page
Productions Last modified: September 2, 2003 |
![[Page Banner Image]](images/hmole.gif){kind=small}
